EGFR and cancer: Even though many studies have been conducted on the selection of antibodies, linkers, and anticancer compounds, further research is warranted to increase the intracellular payload concentration per ADC dose, which will attenuate the adverse effects/anti-cancer activity balance and lead to the successful development of EGFR-targeted ADCs.